← Leaderboards
Marco Bisoffi
New Mexico State University Las Cruces
$722,704
Attributed
$722,704
Total exposure
8
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $171.5K · FY2005–11$200K$150K$100K$50K$0
'05
'06
'07
'08
'09
'10
'11
Funding mix
By agency
NIH$722,704 · 8
By mechanism
P20$572,704 · 7
R03$150,000 · 1
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Proteins”
- David Heimbrook · Leidos Biomedical Research, Inc.$354,061,551
- Randall J Bateman · Washington University$187,292,085
- Paul S. Aisen · Cognition Therapeutics, Inc.$175,382,342
- Reisa A. Sperling · Banner Health$145,046,481
- Barton F Haynes · Duke University$136,029,850
- Joseph L Goldstein · University Of Texas Sw Med Ctr/Dallas$102,433,280
Research focus
ProteinsResearch PersonnelBaseProstatic TissueMalignant Neoplasm Of ProstateTumorStromal CellsTelomereLeadTissuesEpithelialSourceGrantInvestigationSamplingCellsLncapAreaBenignCell ModelProteomicsFundingResourcesSignal Transduction
Grant awards (9)
MARKERS OF PROSTATE CANCER PROGRESSION: A TELOMERE-BASED PROTEOMIC APPROACH$107,416
P20 · FY2011 · RR · contact PI
MARKERS OF PROSTATE CANCER PROGRESSION: A TELOMERE-BASED PROTEOMIC APPROACH$108,501
P20 · FY2010 · RR · contact PI
MARKERS OF PROSTATE CANCER PROGRESSION: A TELOMERE-BASED PROTEOMIC APPROACH$96,544
P20 · FY2009 · RR · contact PI
Targeting Egr-1 with Curcumin Analogs for Prostate Cancer Prevention$75,000
R03 · FY2009 · CA · contact PI
MARKERS OF PROSTATE CANCER PROGRESSION: A TELOMERE-BASED PROTEOMIC APPROACH$94,613
P20 · FY2008 · RR · contact PI
Targeting Egr-1 with Curcumin Analogs for Prostate Cancer Prevention$75,000
R03 · FY2008 · CA · contact PI
MARKERS OF PROSTATE CANCER PROGRESSION: A TELOMERE-BASED PROTEOMIC APPROACH$53,561
P20 · FY2007 · RR · contact PI
MARKERS OF PROSTATE CANCER PROGRESSION: A TELOMERE-BASED PROTEOMIC APPROACH$54,730
P20 · FY2006 · RR · contact PI
MARKERS OF PROSTATE CANCER PROGRESSION: A TELOMERE-BASED PROTEOMIC APPROACH$57,339
P20 · FY2005 · RR